Real-World Study of Adverse Events Associated with Gepant Use in Migraine Treatment Based on the VigiAccess and U.S. Food and Drug Administration’s Adverse Event Reporting System Databases

This study analyzed 23,542 adverse event reports related to gepant medications for migraine treatment from the VigiAccess and FDA databases, focusing on rimegepant, atogepant, and ubrogepant. Rimegepant had the highest incidence of gastrointestinal adverse events, particularly nausea, and was associated with skin disorders like rash and pruritus, as well as alopecia, which was identified as a novel and more severe adverse event. Cardiac adverse events were similar across gepants, but rimegepant had the strongest signals, while ubrogepant showed more musculoskeletal adverse events. The study emphasizes the need for personalized treatment and monitoring of adverse events based on individual patient characteristics, highlighting the importance of understanding the safety profiles of these drugs in real-world settings.